Replies to post #204 on Corvus Pharmaceuticals Inc (CRVS)

[flatlander_60048]

The situation you describe is pretty common with a lot of innovative types. I agree that the focus seems to be constantly shifting. Remember 006 use for Covid? I think focusing on 818 use for T-Cell Lymphoma is the right target. The SOC (chemo) has a miserable PFS rate and it tears down the immune system. So a positive registration trialfor 818 has the potential to launch a front line treatment before the patients immune system and ACL threshold is decimated. CRVS needs to execute a positive mtg with FDA and land a decent partnership. If Miller is correct and 818 has application for solid tumors, immune disorders, etc., the licensing of one indication to bring in the cash infusion will be seen as well worth it.

Hopefully others from Yahoo board follow. Not sure what business model they are following but the dissatisfaction level is off the charts.

Regards FL.

[PatBoone]

I agree; I’m not confident in Miller’s business acumen at all. We need another Bob Duggan to take over. I’ve been following Corvus for a long time. And I know Miller’s weakness well: his tendency to stay with molecules to their bitter ends. I’ve been waiting for data on CPI-818 since 2018. He needs to scrap everything and focus on CPI-818. He will be making the same mistake with CPI-818 that he made with ibrutinib with Pharmacyclics. Nothing in Corvus has any value beside CPI-818. Bob Duggan to give up on his dream of making money with antibiotics at Summit and come take over Corvus.